Menu
← Oncology Approval Tracker
FDA DECISION ·
Breyanzi
lisocabtagene maraleucel · Juno Therapeutics (Bristol Myers Squibb)
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with relapsed or refractory marginal zone lymphoma after at least two prior systemic treatment lines.
LAMPGEN ANALYSIS
Why it matters
The decision introduced the first FDA-approved CAR T-cell therapy for marginal zone lymphoma.
What research teams should watch
Refer to cellular therapy early enough to coordinate leukapheresis, manufacturing, bridging therapy when needed, and post-infusion monitoring.
PRIMARY RECORDS